# Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

> **NCT01097655** · — · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 3049 (actual)

## Conditions studied

- Human Immunodeficiency Virus

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01097655
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 3049 (ACTUAL)
- **Last updated:** 2017-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01097655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01097655, "Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01097655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*